Long-acting risperidone: a review of its role in the treatment of bipolar disorder

被引:14
作者
Kemp, David E. [1 ]
Canan, Fatih [2 ]
Goldstein, Benjamin I. [3 ]
McIntyre, Roger S.
机构
[1] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Mood & Metab Clin, Cleveland, OH 44106 USA
[2] Duzce Univ, Sch Med, Duzce, Turkey
[3] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA
关键词
adherence; bipolar disorder; long-acting risperidone; maintenance phase; risperidone; ANXIETY TREATMENTS CANMAT; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; I-DISORDER; ACUTE MANIA; INJECTABLE RISPERIDONE; STEP-BD; ATYPICAL ANTIPSYCHOTICS; MAINTENANCE THERAPY; TREATMENT ADHERENCE;
D O I
10.1007/s12325-009-0039-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Bipolar disorder is a multidimensional illness typified by fluctuating periods of depression and mania, cognitive dysfunction, abnormal circadian rhythms, and multiple comorbid psychiatric and general medical conditions. Indefinite pharmacological treatment is often required, yet the modest effects of available treatments and frequent difficulties with tolerability and adherence present complex challenges to patients. Long-acting injectable medications offer a therapeutic alternative to oral mood stabilizers and may help facilitate long-term treatment adherence. This article will provide a succinct review of the latest data on the use of long-acting injectable risperidone (LAR) during the maintenance-phase treatment of bipolar disorder. The specific role of LAR in comparison to other atypical antipsychotics, and the limitations of available studies will be discussed from the perspectives of efficacy, tolerability, and sequential positioning in treatment guidelines.
引用
收藏
页码:588 / 599
页数:12
相关论文
共 52 条
[1]   Mortality of patients with mood disorders: follow-up over 34-38 years [J].
Angst, F ;
Stassen, HH ;
Clayton, PJ ;
Angst, J .
JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (2-3) :167-181
[2]   Equivalent switching dose from oral risperidone to risperidone long-acting injection: A 48-week randomized, prospective, single-blind pharmacokinetic study [J].
Bai, Ya Mei ;
Chen, Tzu Ting ;
Chen, Jen-Yeu ;
Chang, Wen-Ho ;
Wu, Bojian ;
Hung, Chih Hung ;
Lin, Wen Kuo .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (08) :1218-1225
[3]  
BRECHER M, 2008, ANN M AM PSYCH ASS 2
[4]   Bipolar drug development: Are we getting closer to the real world? [J].
Calabrese, Joseph R. ;
Kemp, David E. .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (10) :1234-1236
[5]   Olanzapine: review of safety [J].
Citrome, L. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) :140-150
[6]  
*CLIN TRIALS WEBS, STUD EV EFF SAF EXT
[7]   Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia [J].
Eerdekens, M ;
Van Hove, I ;
Remmerie, B ;
Mannaert, E .
SCHIZOPHRENIA RESEARCH, 2004, 70 (01) :91-100
[8]  
FREYBERGER HJ, 2002, INT J NEUROPSYCHO S1, V5, P189
[9]   Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder [J].
Gianfrancesco, Frank D. ;
Sajatovic, Martha ;
Rajagopalan, Krithika ;
Wang, Ruey-Hua .
CLINICAL THERAPEUTICS, 2008, 30 (07) :1358-1374
[10]   Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder [J].
Han, Changsu ;
Lee, Moon-Soo ;
Pae, Chi-Un ;
Ko, Young-Hoon ;
Patkar, Ashwin A. ;
Jung, In-Kwa .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (06) :1219-1223